Blair William & Co. IL Has $8.22 Million Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)

Blair William & Co. IL increased its stake in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 9.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 114,129 shares of the biotechnology company's stock after purchasing an additional 9,459 shares during the period. Blair William & Co. IL owned 0.07% of Bio-Techne worth $8,221,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. UMB Bank n.a. raised its position in shares of Bio-Techne by 46.4% during the fourth quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 168 shares during the last quarter. Brooklyn Investment Group acquired a new stake in Bio-Techne in the third quarter worth about $39,000. Quest Partners LLC bought a new stake in Bio-Techne during the 3rd quarter worth about $43,000. MassMutual Private Wealth & Trust FSB lifted its position in Bio-Techne by 60.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 672 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 253 shares during the period. Finally, Versant Capital Management Inc boosted its stake in shares of Bio-Techne by 35.0% in the 4th quarter. Versant Capital Management Inc now owns 763 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 198 shares during the last quarter. Institutional investors and hedge funds own 98.95% of the company's stock.

Bio-Techne Trading Down 5.1 %

TECH stock traded down $2.97 during midday trading on Thursday, hitting $55.41. 388,491 shares of the company's stock were exchanged, compared to its average volume of 1,562,801. Bio-Techne Co. has a one year low of $55.25 and a one year high of $85.57. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.77 and a current ratio of 3.94. The company has a market cap of $8.76 billion, a PE ratio of 55.97, a price-to-earnings-growth ratio of 2.88 and a beta of 1.30. The stock's fifty day moving average price is $65.38 and its 200-day moving average price is $71.12.

Remove Ads

Bio-Techne (NASDAQ:TECH - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. Research analysts predict that Bio-Techne Co. will post 1.67 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Monday, February 17th were issued a $0.08 dividend. This represents a $0.32 annualized dividend and a dividend yield of 0.58%. The ex-dividend date was Friday, February 14th. Bio-Techne's dividend payout ratio (DPR) is presently 32.32%.

Insider Transactions at Bio-Techne

In other news, CEO Kim Kelderman sold 13,392 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the completion of the transaction, the chief executive officer now directly owns 39,004 shares of the company's stock, valued at $3,014,619.16. This trade represents a 25.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Amy E. Herr sold 1,860 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $65.96, for a total transaction of $122,685.60. Following the completion of the sale, the director now directly owns 1,976 shares in the company, valued at approximately $130,336.96. This represents a 48.49 % decrease in their position. The disclosure for this sale can be found here. 3.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Baird R W lowered shares of Bio-Techne from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Scotiabank upped their target price on shares of Bio-Techne from $88.00 to $90.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 6th. Robert W. Baird lowered Bio-Techne from an "outperform" rating to a "neutral" rating and reduced their price target for the stock from $88.00 to $68.00 in a research report on Wednesday, February 19th. Evercore ISI started coverage on Bio-Techne in a report on Tuesday, March 18th. They issued an "outperform" rating and a $75.00 price objective for the company. Finally, StockNews.com lowered Bio-Techne from a "buy" rating to a "hold" rating in a research note on Wednesday, March 26th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $81.25.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.